China's 520,000 July COVID cases are a vaccine logistics problem, not a factory one

Start with the ratio buried in the Chinese CDC's own release: 487 severe cases and one recorded death against 522,000 reported infections in July, which works out to about one severe case per 1,072 reported and one death per 522,000 ^[1][15]. Nothing in that arithmetic resembles the 2020 event that shut plants and rerouted freight, and Chinese authorities say the increase has slowed, that some regions are declining, and that most infections are mild ^[4].

The direction is still worth reading, but read it off the right instrument. A confirmed case count is a function of how many people test; sentinel positivity is a rate. Across 1,041 sentinel hospitals the positivity rate among respiratory-symptom outpatients went 8.2, 11.2, 15.3, 19.5, then 21.2 percent, a 13 point move and a 2.6-fold rise in five weeks ^[2][16]. That is the number to track, and it is also the one that has since flattened by Beijing's account ^[4].

Korea's 9.1 percent looks worse on its own than in context. In the same week 33 samples, the overall respiratory virus detection rate was 59.7 percent, with parainfluenza at 20.5 percent and rhinovirus at 14.8 percent ^[5][7]. COVID is roughly a sixth of everything the 106 reporting institutions are finding, third in line behind two viruses nobody is building a procurement plan around ^[17]. The Korean series is also not a clean climb: it went 3.2, 5.9, 5.7, then 9.1 percent, dipping between weeks 31 and 32 before jumping about 60 percent week on week ^[6][19][18].

So the real constraint is inventory and calendar. Korea has secured 4.84 million doses for the year ^[9], and industry officials say demand tends to concentrate in the first one to two weeks when flu and COVID vaccinations begin together ^[12]. Last year some institutions ran out faster than expected and older adults missed their slot, and because doses take time to produce and distribute there is little room to top up once a wave is underway ^[13]. Taiwan is the live demonstration: rising patient numbers have already produced temporary vaccine shortages in some areas ^[8].

Moderna's variant-targeting Spikevax prefilled syringe won approval from Korea's Ministry of Food and Drug Safety on the 6th ^[10], which matters given that NB.1.8.1 and its sublineages accounted for 99.0 percent of the most recent week's Chinese sequences and all 11,204 July genomes were Omicron ^[3]. Approval is not stock on a shelf, though, and the free program covers a defined group: people 65 and over, patients and residents at infection-vulnerable facilities, and the immunocompromised ^[11].

The loss from getting this wrong is not revenue. As one industry official put it, older adults often do not return to a clinic once they miss their vaccination window ^[14]. A dose that arrives in week four for someone who queued in week one is frequently a dose never administered, and no amount of later supply recovers it.